Spotlight On... Can Shire make the most of Baxalta's hemophilia meds?; AZ brings new blood into corp comms; Stricter DTC oversight expected in India; and more...

Shire ($SHPG) CEO Flemming Ornskov says his own goals for cost savings, post-merger with Baxalta ($BXLT), are higher than the company's stated $500 million. But analysts are still skeptical of the deal; they're particularly worried about stepped-up competition in hemophilia with new meds hitting the market. More from FiercePharma

> AstraZeneca ($AZN) has some new faces on its global communications team, with Neil Burrows as head of global media relations and Ali Perkins as head of communications for global medicines development. Report

> Indian drugmakers expect stricter curbs on consumer advertising. Though DTC campaigns are technically prohibited, the laws have loopholes, experts say. Report

> Sanofi's ($SNY) Korean unit and LG Life Sciences are locked in a dispute over a co-promotion deal on LG's top diabetes meds. Report

> Antidepressant treatment helps diabetics control their blood sugar, a new study found, potentially spurring more patients with both disorders to seek treatment. Report

And Finally... Kids with Type 1 diabetes are finding comfort in American Girl dolls styled as diabetics. Report

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.